iRhythm Technologies

IRTC

Market cap $5.84B

SAN FRANCISCO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the third quarter 2025 after the close of trading on Thursday, October 30, 2025. The company's management team will host a corresponding conference call beginning at 1:30 p.m.

NEW YORK and NEW ORLEANS, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into iRhythm Technologies, Inc. (NasdaqGS: IRTC).

iRhythm Technologies, Inc. (NASDAQ:IRTC ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 2:35 PM EDT Company Participants Quentin Blackford - President, CEO & Director Conference Call Participants Patrick Wood - Morgan Stanley, Research Division Presentation Patrick Wood MD of Equity Research Okay. Welcome. Thanks for everyone joining day 2 of BMS Global Healthcare Conference.

iRhythm's AMALFI trial shows its Zio monitoring service boosts AF detection and speeds diagnosis, strengthening its edge in cardiac care.

SAN FRANCISCO, Aug. 29, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) announced results from the Oxford University-led A ctive M onitoring for A tria L FI brillation (AMALFI) randomized clinical trial, presented at the European Society of Cardiology (ESC) Congress 2025 and simultaneously published in the Journal of the American Medical Association (JAMA) , demonstrating that home-based screening with the Zio® long-term continuous monitoring (LTCM) service led to increased atrial fibrillation (AFib) detection and a shorter time to diagnosis.

SAN FRANCISCO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that its management team is scheduled to present at the following investor conferences.

Spruce Point Capital Management issued a detailed report on iRhythm Technologies, Inc. IRTC on Monday, projecting a long-term downside risk of 40% to 70% for its stock.

SAN FRANCISCO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc . (NASDAQ:IRTC) announced the publication of the real-world evidence study: Assessment of Variation in AmbuLatory Cardiac MONitoring: Real-World Evidence of Commercially Insured Beneficiaries (AVALON) in the American Journal of Managed Care reinforcing the clinical superiority of the Zio® long-term continuous monitoring (LTCM) service.

iRhythm Technologies (IRTC 17.81%), a medical device company specializing in cardiac monitoring technology, reported its Q2 FY2025 results on July 31, 2025. The highlight was record revenue (GAAP) of $186.7 million, up 26.1% from the previous year and beating analyst expectations by $12.7 million.

iRhythm Technologies, Inc. (NASDAQ:IRTC ) Q2 2025 Earnings Conference Call July 31, 2025 4:30 PM ET Company Participants Daniel G. Wilson - CFO & Principal Financial Officer Quentin S.